Pioneers in Medical Robotics
AVRA’s ( OTC: AVMR ) medical team were among the earliest adopters to perform robotically assisted, minimally-invasive surgery. Surgical robotic systems have yet to realize their potential in terms of improved accuracy, navigation, targeting, imaging and visualization, allowing for penetration into all aspects of surgical care. AVRA’s Surgeons are partnering with engineers and scientists to design and develop a novel, computer-integrated, semi/autonomous robotic platform that is truly disruptive.
Market Opportunity: Aesthetic Medicine
AVRA is currently developing a unique surgical robotic platform in the field of Aesthetics. The proprietary intelligent AVRA Instrument Guidance System (AIGS) will enable surgeons to simulate procedures for preoperative review prior to performing surgery. Patient specific mapping optimizes results both for the surgeon and the patient.
According to the American Society for Aesthetic Plastic Surgery (ASAPS), the field of aesthetics is a $13.5 billion industry, with explosive growth in non-surgical treatments.
Farhan Taghizadeh, MD
AVRA Chief Medical Officer
Dr. Taghizadeh is a board-certified ENT, Plastic & Reconstructive surgeon. He is considered a global authority on cosmetic surgery. He heads the aesthetics initiative at AVRA. He has extensively published on robotic facial surgery and has performed over 3,500 facelifts.
Patient Inspired Technology
AVRA is a surgical digital technology company whose primary goal is to provide surgeons with the ability to achieve consistently excellent results for the patient. Employing advanced technology, AVRA is developing an intelligent robotic platform combining attributes of imaging with target acquisition and guidance to navigate with unprecedented accuracy and precision. These advanced, semi/autonomous systems will have boundless diagnostic and therapeutic applications – Target, Diagnose, Treat.